Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Owlet Q4 2025 Earnings Call - Subscription Momentum: 110,000 Owlet360 Subscribers and Path to Recurring Revenue Growth
Owlet closed 2025 with a record year, driven by the launch and rapid scaling of its Owlet360 subscription and the Dream product suite. Full year revenue hit $105.7 million, up 35.4% year over year, an...
- Owlet reported Q4 2025 revenue of $26.6 million, up 29.6% year over year, and full year 2025 revenue of $105.7 million, up 35.4% versus 2024.
- Owlet360 subscription reached over 110,000 paying subscribers as of early March, marking the first full year of the service since its January 2025 launch.
- Full year 2025 gross margin was a record 50.6% despite tariff headwinds, Q4 gross margin was 47.6% which included an estimated 510 basis point tariff impact.
- +17 more takeaways
AudioEye Q4 2025 Earnings Call - Guides 30% Adjusted EBITDA Growth in 2026, Betting on AI Efficiency and ARR Acceleration
AudioEye closed 2025 with streaky momentum and cleaner economics. The company reported its 40th consecutive quarter of sequential revenue growth, record full-year revenue, and a 35% jump in adjusted E...
- AudioEye reported its 40th consecutive quarter of sequential revenue growth and record full-year 2025 revenue.
- Adjusted EBITDA for 2025 was a record $9.1 million, up approximately 35% year-over-year, with an adjusted EBITDA margin of 22%.
- Management guides 2026 adjusted EBITDA to grow by at least 30%, implying at least $11.8 million for the year and a run rate target of $15 million by year-end driven by AI efficiencies.
- +14 more takeaways
Atea Pharmaceuticals Fourth Quarter 2025 Earnings Call - Phase 3 HCV readouts set to define 2026 with cash runway through 2027
Atea says 2026 is a make-or-break year. The company expects top-line results from its global phase 3 HCV program this year, with C-BEYOND readout midyear and C-FORWARD by year-end, while maintaining r...
- Company-wide focus for 2026 is delivery of phase 3 HCV top-line readouts: C-BEYOND midyear and C-FORWARD by year-end.
- HCV regimen under study is bemnifosbuvir plus ruzasvir, evaluated head-to-head versus sofosbuvir/velpatasvir (Epclusa).
- Atea states its global phase 3 program will enroll more than 1,760 patients across two trials, C-BEYOND (North America) and C-FORWARD (rest of world).
- +13 more takeaways
a.k.a. Brands Holding Corp. Q4 FY2025 Earnings Call - Guides FY2026 as an Inflection Year with Mid-Single Digit Sales Growth and Material EBITDA Expansion
a.k.a. Brands closed FY25 with modest top-line growth and a recalibrated foundation, and management is calling 2026 an inflection year. The company grew net sales 4.4% to $600 million, sharpened inven...
- FY25 net sales grew 4.4% to $600.0 million, 5.0% on a constant currency basis.
- Management calls FY26 an inflection year, guiding net sales of $625 million to $635 million, and adjusted EBITDA of $27 million to $29 million.
- Tariffs were a material headwind in FY25, management estimates roughly 100 basis points of gross margin pressure from tariff-related sourcing costs.
- +11 more takeaways
TriSalus Life Sciences Fourth Quarter 2025 Earnings Call - $46M Raise, Doubling Sales Force and Reaffirming $60-62M 2026 Revenue with Back-Loaded Growth
TriSalus closed 2025 with strong top-line momentum, raising $46 million in a well-subscribed public offering and reporting Q4 revenue of $13.2 million and full-year revenue of $45.2 million. Managemen...
- Q4 2025 revenue was $13.2 million, up 60% year over year; full-year 2025 revenue was $45.2 million, up 53% year over year.
- TriSalus completed a public offering in February that raised $46 million in gross proceeds, the deal was more than two times oversubscribed and brought in fundamental healthcare investors.
- Management reaffirmed 2026 revenue guidance at $60 million to $62 million, and expects roughly 40% of 2026 revenue in H1 and 60% in H2 due to onboarding and territory realignment.
- +11 more takeaways
AerSale Q4 2025 Earnings Call - Shift to recurring revenue and disciplined feedstock buying drives margin expansion
AerSale closed 2025 with improving profitability despite a stumble in headline revenue. Q4 adjusted EBITDA rose to $15.2 million, up 17.1% year over year, while full year adjusted EBITDA surged to $46...
- Q4 adjusted EBITDA was $15.2 million, up 17.1% versus Q4 2024.
- Full year 2025 adjusted EBITDA rose to $46.1 million, up 38.2% year over year; full year revenue was $335.3 million, down 2.8%.
- Q4 revenue was $90.9 million, down 4% YoY; management says excluding flight equipment sales revenue increased about 9.8%.
- +12 more takeaways
Inuvo, Inc. Q4 2025 Earnings Call - IntentKey pivot targets higher-margin data and enterprise deals as Platforms revenue rebalances
Inuvo reported a sharp fourth quarter platform revenue pullback while pushing a strategic pivot toward IntentKey, its AI-driven intent product, as the path to higher-margin, recurring data and enterpr...
- Q4 2025 revenue was $14.3 million, a 46% decline versus Q4 2024, driven by an intentional pullback in platform products.
- Q4 gross profit fell to $9.5 million, down 56% year over year, and Q4 operating loss was $1.2 million.
- Q4 net loss was $594,000, or $0.04 per share, while adjusted EBITDA for the quarter was $360,000.
- +15 more takeaways
BioLargo 2025 Annual Earnings Call - Commercial inflection as Clyra launches and EPA monitors AEC PFAS demo
BioLargo frames 2025 as a pivot year, moving from development to commercialization across four proprietary platforms. Management points to concrete validation events: Clyra Medical shipped its first p...
- Company filed its 10-K and positions 2025 as a decisive transition from R&D to commercialization across four platforms: Clyra Medical, Cellinity Battery, AEC Water Treatment, and ONM Environmental.
- BioLargo retains significant equity in its subsidiaries, reported ownership stakes ranging from 49% to 100%, and receives a 6% royalty on sales as a recurring corporate revenue stream.
- Clyra Medical: ViaCLYR is FDA 510(k) cleared, presented clinical data at the 48th Annual Boswick Symposium, and the company has an exclusive distribution agreement with a large distributor, with its first commercial stocking order shipped and paid.
- +12 more takeaways
Intrepid Potash, Inc. Fourth Quarter 2025 Earnings Call - Trio Surge and Maiden Lithium Resource Put Growth Back on the Table
Intrepid closed 2025 with a clear breakout year, driven by record Trio volumes, stronger pricing, and tighter unit costs. Adjusted EBITDA of $63 million, roughly an 80 percent improvement year over ye...
- Adjusted EBITDA for 2025 was $63 million, an almost 80% improvement versus 2024; Q4 adjusted EBITDA was $18.1 million and adjusted net income was $6.5 million.
- Total fertilizer sales volumes in 2025 reached ~592,000 tons, about 20% higher than 2024; Trio sales hit a company record at 303,000 tons.
- Trio delivered the strongest segment performance in company history outside of 2022 pricing, with Q4 realized Trio price of $379 per ton, and a 20% price gain versus Q1 2025.
- +12 more takeaways
Ring Energy Q4 2025 Earnings Call - Discipline Pays: Free Cash Flow, Debt Paydown and Testing Horizontal Upside
Ring closed 2025 having quietly proved its playbook: generate cash, cut costs, pay down debt, and test new horizontal inventory without blowing up the balance sheet. Despite a post-Liberation Day pric...
- Ring delivered its 25th consecutive quarter of adjusted free cash flow, generating $5.7 million in Q4 and $50.1 million for full-year 2025 despite an 18% drop in realized commodity pricing year over year.
- Q4 production sold 20,508 Boe/d, essentially flat sequentially, and 2025 full-year average sales set a company record at 20,253 Boe/d, helped by nine months of production from the March Lime Rock acquisition.
- Realized price fell to $35.45 per Boe in Q4, down 14% from Q3, driven by an 11% sequential decline in realized oil pricing and wider differentials versus NYMEX WTI.
- +12 more takeaways